TNF and inflammatory bowel disease: Healthcare providers should be aware that pharmacotherapeutic agents commonly used to reduce inflammation and manage symptoms in IBD patients, such as corticosteroids, 5-aminosalicylic acid (5-ASA), thiopurines, and immunotherapies, like TNF-α or Janus kinase (JAK) inhibitors, may have implications for ASCVD [52, 53].